Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · regulatory

Nigeria turns to Uganda for sickle-cell treatment

13 September 2026 · By · Wire by Fusion42

Published

13 September 2026

Topic

regulatory

◆ Sectors

Health

◆ Geography

Nigeria

◆ Source

Read at monitor.co.ug →

◆ Verified

Fusion42 · 13 September 2026 · Fusion42 review

Nigeria is partnering with Ugandan pharmaceutical companies to access hydroxyurea for treating sickle-cell disease, addressing the highest global burden of the disease in Nigeria. The collaboration was discussed during the Nigeria-Uganda Business Forum 2026, alongside plans to boost trade in agro-processing and livestock.

This Wire brief sits within Fusion42's coverage of Health.

◆ ◆ The Wire takeaway

You can leverage new drug access channels in Nigeria as Ugandan pharmaceutical makers supply hydroxyurea for sickle-cell treatment, opening a path to tap under-served patient populations. This partnership also signals fresh cross-border health product flows you can build on this year.

◆ Coverage

1 source · 13 Sep 2026

◆ Related on Wire

◆ Topics

Healthsickle-cellhealthcare-collaborationpharmaceuticalsnigeria-ugandatradehydroxyurea